Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Lisa GENORE |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
Hyperbaric oxygen therapy for the treatment of children and youth with Autism Spectrum Disorders: An evidence-based systematic review / Cynthia GOLDFARB in Research in Autism Spectrum Disorders, 29-30 (September–October 2016)
[article]
Titre : Hyperbaric oxygen therapy for the treatment of children and youth with Autism Spectrum Disorders: An evidence-based systematic review Type de document : Texte imprimé et/ou numérique Auteurs : Cynthia GOLDFARB, Auteur ; Lisa GENORE, Auteur ; Carolyn HUNT, Auteur ; Janine FLANAGAN, Auteur ; Mark HANDLEY-DERRY, Auteur ; Anita JETHWA, Auteur ; Nicola JONES-STOKREEF, Auteur ; S. M. L. KIRKPATRICK, Auteur ; A. RICHARDS, Auteur ; Lillian ROJNICA, Auteur ; Clive SCHWARTZ, Auteur ; David SHAWN, Auteur ; Diann SUPERINA-BELL, Auteur ; Elizabeth YOUNG, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : p.1-7 Langues : Anglais (eng) Mots-clés : Autism Hyperbaric oxygen therapy Treatment Review Index. décimale : PER Périodiques Résumé : AbstractBackground Autism Spectrum Disorder (ASD) is a common disorder that has a complex and heterogeneous etiology. Some evidence suggests that inflammation and oxidative stress may have a pathophysiological link. Hyperbaric Oxygen Therapy (HBOT) has been proposed as a possible therapy. Because HBOT is an expensive treatment with significant commercial opportunity, it is essential for it to have a research evidence base prior to widespread use. Objective To conduct a systematic review of the literature evaluating the clinical impact of HBOT on behavior and development in ASD with a view to inform practice. Methods A literature search of electronic scientific databases focusing on clinical outcomes of HBOT in ASD was performed. Articles meeting inclusion criteria were independently assessed by reviewers and were classified according to the American Academy of Neurology Guidelines. Recommendations were made based on the evidence. Results Five articles were reviewed with data extraction. Based on the AAN Classification of Recommendations the data supported a rating of “A”, indicating that HBOT is not effective for treating children and youth with ASD. Conclusions Current evidence does not support HBOT as an effective treatment for children and youth with ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2016.05.004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=292
in Research in Autism Spectrum Disorders > 29-30 (September–October 2016) . - p.1-7[article] Hyperbaric oxygen therapy for the treatment of children and youth with Autism Spectrum Disorders: An evidence-based systematic review [Texte imprimé et/ou numérique] / Cynthia GOLDFARB, Auteur ; Lisa GENORE, Auteur ; Carolyn HUNT, Auteur ; Janine FLANAGAN, Auteur ; Mark HANDLEY-DERRY, Auteur ; Anita JETHWA, Auteur ; Nicola JONES-STOKREEF, Auteur ; S. M. L. KIRKPATRICK, Auteur ; A. RICHARDS, Auteur ; Lillian ROJNICA, Auteur ; Clive SCHWARTZ, Auteur ; David SHAWN, Auteur ; Diann SUPERINA-BELL, Auteur ; Elizabeth YOUNG, Auteur ; Evdokia ANAGNOSTOU, Auteur . - p.1-7.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 29-30 (September–October 2016) . - p.1-7
Mots-clés : Autism Hyperbaric oxygen therapy Treatment Review Index. décimale : PER Périodiques Résumé : AbstractBackground Autism Spectrum Disorder (ASD) is a common disorder that has a complex and heterogeneous etiology. Some evidence suggests that inflammation and oxidative stress may have a pathophysiological link. Hyperbaric Oxygen Therapy (HBOT) has been proposed as a possible therapy. Because HBOT is an expensive treatment with significant commercial opportunity, it is essential for it to have a research evidence base prior to widespread use. Objective To conduct a systematic review of the literature evaluating the clinical impact of HBOT on behavior and development in ASD with a view to inform practice. Methods A literature search of electronic scientific databases focusing on clinical outcomes of HBOT in ASD was performed. Articles meeting inclusion criteria were independently assessed by reviewers and were classified according to the American Academy of Neurology Guidelines. Recommendations were made based on the evidence. Results Five articles were reviewed with data extraction. Based on the AAN Classification of Recommendations the data supported a rating of “A”, indicating that HBOT is not effective for treating children and youth with ASD. Conclusions Current evidence does not support HBOT as an effective treatment for children and youth with ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2016.05.004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=292 A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism / Deepali MANKAD in Molecular Autism, (March 2015)
[article]
Titre : A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism Type de document : Texte imprimé et/ou numérique Auteurs : Deepali MANKAD, Auteur ; Annie DUPUIS, Auteur ; Sharon SMILE, Auteur ; Wendy ROBERTS, Auteur ; Jessica BRIAN, Auteur ; Toni LUI, Auteur ; Lisa GENORE, Auteur ; Dina ZAGHLOUL, Auteur ; Alana IABONI, Auteur ; Peggy Margaret A. MARCON, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : p.1-11 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the absence of any medications known to improve core symptom domains, parents often use complementary alternative treatments, including omega-3 fatty acid supplements. En ligne : http://dx.doi.org/10.1186/s13229-015-0010-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=277
in Molecular Autism > (March 2015) . - p.1-11[article] A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism [Texte imprimé et/ou numérique] / Deepali MANKAD, Auteur ; Annie DUPUIS, Auteur ; Sharon SMILE, Auteur ; Wendy ROBERTS, Auteur ; Jessica BRIAN, Auteur ; Toni LUI, Auteur ; Lisa GENORE, Auteur ; Dina ZAGHLOUL, Auteur ; Alana IABONI, Auteur ; Peggy Margaret A. MARCON, Auteur ; Evdokia ANAGNOSTOU, Auteur . - p.1-11.
Langues : Anglais (eng)
in Molecular Autism > (March 2015) . - p.1-11
Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the absence of any medications known to improve core symptom domains, parents often use complementary alternative treatments, including omega-3 fatty acid supplements. En ligne : http://dx.doi.org/10.1186/s13229-015-0010-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=277